Autolus Therapeutics Q3 2024 Update
Ticker: AUTL · Form: 10-Q · Filed: 2024-11-12T00:00:00.000Z
Sentiment: neutral
Topics: biotech, clinical-stage, financials, cash-burn
TL;DR
Autolus burned £104.7M in 9 months, has £244.9M cash left. Still burning cash.
AI Summary
Autolus Therapeutics plc filed its 10-Q for the period ending September 30, 2024. The company reported operating expenses of £104.7 million for the nine months ended September 30, 2024, compared to £102.5 million for the same period in 2023. As of September 30, 2024, Autolus had cash and cash equivalents of £244.9 million.
Why It Matters
This filing provides insight into Autolus Therapeutics' financial health and operational spending as they advance their cell therapy programs, crucial for investor and stakeholder confidence.
Risk Assessment
Risk Level: medium — The company is in the clinical development phase, which is inherently risky and requires significant ongoing investment.
Key Numbers
- £104.7M — Operating Expenses (9M 2024) (Represents significant investment in R&D and operations.)
- £244.9M — Cash and Cash Equivalents (Sep 30, 2024) (Indicates the company's liquidity position.)
Key Players & Entities
- Autolus Therapeutics plc (company) — Filer of the 10-Q
- 20240930 (date) — End of reporting period
- £104.7 million (dollar_amount) — Operating expenses for nine months ended Sep 30, 2024
- £102.5 million (dollar_amount) — Operating expenses for nine months ended Sep 30, 2023
- £244.9 million (dollar_amount) — Cash and cash equivalents as of Sep 30, 2024
FAQ
What were Autolus Therapeutics' total operating expenses for the nine months ended September 30, 2024?
Autolus Therapeutics reported operating expenses of £104.7 million for the nine months ended September 30, 2024.
How much cash and cash equivalents did Autolus Therapeutics have as of September 30, 2024?
As of September 30, 2024, Autolus Therapeutics had £244.9 million in cash and cash equivalents.
How do the operating expenses for the first nine months of 2024 compare to the same period in 2023?
Operating expenses increased slightly from £102.5 million for the nine months ended September 30, 2023, to £104.7 million for the same period in 2024.
What is the fiscal year end for Autolus Therapeutics plc?
The fiscal year end for Autolus Therapeutics plc is December 31.
What was the filing date for this 10-Q report?
This 10-Q report was filed on November 12, 2024.
From the Filing
0001730463-24-000136.txt : 20241112 0001730463-24-000136.hdr.sgml : 20241112 20241112162729 ACCESSION NUMBER: 0001730463-24-000136 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 153 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 241448743 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 10-Q 1 autl-20240930.htm 10-Q autl-20240930 0001730463 false 2024 Q3 12/31 True xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:shares xbrli:pure autl:financialInstrument autl:unit autl:performanceObligation autl:vote autl:payment autl:contract autl:director 0001730463 2024-01-01 2024-09-30 0001730463 dei:AdrMember 2024-01-01 2024-09-30 0001730463 autl:OrdinarySharesMember 2024-01-01 2024-09-30 0001730463 2024-11-08 0001730463 2024-09-30 0001730463 2023-12-31 0001730463 autl:OrdinarySharesMember 2024-09-30 0001730463 autl:OrdinarySharesMember 2023-12-31 0001730463 autl:DeferredClassASharesMember 2024-09-30 0001730463 autl:DeferredClassASharesMember 2023-12-31 0001730463 autl:DeferredClassBSharesMember 2024-09-30 0001730463 autl:DeferredClassBSharesMember 2023-12-31 0001730463 autl:DeferredClassCSharesMember 2024-09-30 0001730463 autl:DeferredClassCSharesMember 2023-12-31 0001730463 us-gaap:LicenseMember 2024-07-01 2024-09-30 0001730463 us-gaap:LicenseMember 2023-07-01 2023-09-30 0001730463 us-gaap:LicenseMember 2024-01-01 2024-09-30 0001730463 us-gaap:LicenseMember 2023-01-01 2023-09-30 0001730463 2024-07-01 2024-09-30 0001730463 2023-07-01 2023-09-30 0001730463 2023-01-01 2023-09-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2024-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2024-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2024-06-30 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001730463 us-gaap:RetainedEarningsMember 2024-06-30 0001730463 2024-06-30 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-07-01 2024-09-30 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001730463 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-09-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2024-09-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2024-09-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2024-09-30 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001730463 us-gaap:RetainedEarningsMember 2024-09-30 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2023-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassASharesMember 2023-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassBSharesMember 2023-06-30 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2023-06-30 0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 00